Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status
OBJECTIVE: In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment.
METHODS: The newly developed Case-Background method was used to estimate odds ratios for the impacts of various sociodemographic factors on sorafenib access in clinically eligible patients. Socioeconomic status was defined as a factor of median income and education level based on ZIP code of residence.
RESULTS: There was a strong association between sorafenib prescription and residence in an area of higher SES. While controlling for age, race/ethnicity, and insurance status, high SES residence doubled the odds of sorafenib prescription (OR=2.05, p<.01).
CONCLUSIONS: Low socioeconomic status communities appear to have a reduced chance of receiving the only effective treatment for advanced HCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of health care for the poor and underserved - 29(2018), 3 vom: 30., Seite 1123-1134 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sarpel, Umut [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9ZOQ3TZI87 |
|---|
| Anmerkungen: |
Date Completed 25.04.2019 Date Revised 24.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1353/hpu.2018.0083 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287613577 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287613577 | ||
| 003 | DE-627 | ||
| 005 | 20231225054416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1353/hpu.2018.0083 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0958.xml |
| 035 | |a (DE-627)NLM287613577 | ||
| 035 | |a (NLM)30122687 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarpel, Umut |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2019 | ||
| 500 | |a Date Revised 24.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment | ||
| 520 | |a METHODS: The newly developed Case-Background method was used to estimate odds ratios for the impacts of various sociodemographic factors on sorafenib access in clinically eligible patients. Socioeconomic status was defined as a factor of median income and education level based on ZIP code of residence | ||
| 520 | |a RESULTS: There was a strong association between sorafenib prescription and residence in an area of higher SES. While controlling for age, race/ethnicity, and insurance status, high SES residence doubled the odds of sorafenib prescription (OR=2.05, p<.01) | ||
| 520 | |a CONCLUSIONS: Low socioeconomic status communities appear to have a reduced chance of receiving the only effective treatment for advanced HCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Sorafenib |2 NLM | |
| 650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
| 700 | 1 | |a Heskel, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Spivack, John Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Feferman, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a Ang, Celina |e verfasserin |4 aut | |
| 700 | 1 | |a Gany, Francesca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of health care for the poor and underserved |d 1997 |g 29(2018), 3 vom: 30., Seite 1123-1134 |w (DE-627)NLM012893994 |x 1548-6869 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2018 |g number:3 |g day:30 |g pages:1123-1134 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1353/hpu.2018.0083 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2018 |e 3 |b 30 |h 1123-1134 | ||